As per the research report, the size of the Middle East and Africa Intravenous Ibuprofen Market was valued at USD 0.68 billion in 2022 and estimated to be growing at a CAGR of 19.75%, reaching USD 1.68 billion by 2027 during the forecast period 2022 to 2027.
High bioavailability with immediate effect, as well as an increase in conditions such as CVS, osteoarthritis, rheumatoid arthritis, cancer, and headache, are driving the expansion of the intravenous ibuprofen market. In addition, Ibuprofen's over-the-counter availability across Africa is boosting the market growth.
The industry is growing in demand as people become more aware of quick pain relief injections and pharmaceutical companies focus on developing new medications. In addition, as disposable income rises in urban areas, the Middle East and Africa market's growth rate is leveling.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing the coronavirus disease 2019 pandemic, which is quickly spreading throughout the continent. Fever, dry cough, exhaustion, sore throat, diarrhea, and other clinical signs are common in SARS-CoV-2 patients. Ibuprofen intravenous (IV) is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation caused by a disease, surgical operations, trauma, or an acute illness. IV ibuprofen is used for the treatment of postoperative and acute pain.
The demand for Ibuprofen has increased due to the side effects of opioid analgesics, such as respiratory depression, allergic responses, drowsiness, and gastrointestinal problems.
Some limitations limiting the intravenous Ibuprofen Middle East and Africa market are the adverse effects of intravenous ibuprofen injection and the time it takes to introduce new products. Nevertheless, the ibuprofen injection market is expected to rise due to technological advancements and investments in research and development.
Ibuprofen has its own set of hazards, some of which are only now becoming apparent. Nausea, dizziness, headache, allergic reactions, gastrointestinal distress (vomiting, diarrhea, constipation, stomach bleeding), and elevated blood pressure are all common adverse effects.
Several limitations, such as the lengthy licensing process and geographical restrictions, will likely stifle market expansion.
This research report on the MEA Intravenous Ibuprofen Market has been segmented and sub-segmented into the following categories.
By Age Group:
Geographically, the Middle East & Africa Intravenous Ibuprofen Market is predicted to increase at a high rate due to the factors such as discomfort, fever, headache, toothache, back pain, and trauma that have been linked to this region.
The market for intravenous Ibuprofen for pain management is still in its infancy. However, the FDA approved IV ibuprofen for pediatric use in 2015, and the market is likely to rise significantly throughout the projection period.
The Saudi Arabia intravenous ibuprofen market is expected to dominate the intravenous market in the Middle East and Africa. Modern technologies such as high throughput, bioinformatics, and combinatorial chemistry are frequently used for better drug candidate identification. In addition, emerging technologies have considerably aided drug discovery, making the process more refined, accurate, and time-efficient.
The UAE intravenous ibuprofen market will likely have a significant share of the intravenous market in the Middle East and Africa. During the projected period, growth in the incidence of rheumatoid arthritis disease is expected to boost the market in the area.
The South African intravenous ibuprofen market is predicted to grow at a healthy CAGR due to the increased prevalence of cancer, cardiovascular disorders, pain, arthritis, and a shift in the usage of non-opioid medications with a substantial impact on market growth.
KEY MARKET PLAYERS
The leading companies dominating the MEA Intravenous Ibuprofen Market profiled in the report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, and Sandor Medicaids Pvt Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., and Laboratorios Valmorca, C.A.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com